Imunon (NASDAQ:IMNN) Given New $12.00 Price Target at HC Wainwright

Imunon (NASDAQ:IMNN) had its price objective lowered by HC Wainwright from $14.00 to $12.00 in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Stock Performance

Shares of IMNN opened at $0.75 on Monday. The stock has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.18. The stock has a market capitalization of $44.92 million, a price-to-earnings ratio of -0.40 and a beta of 2.14. Imunon has a one year low of $0.48 and a one year high of $3.65.

Imunon (NASDAQ:IMNN) last issued its earnings results on Wednesday, August 14th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04. On average, analysts predict that Imunon will post -1.68 earnings per share for the current year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.